Decoupled Glucose and Lipid Metabolic Recovery after Viral Clearance in Direct-Acting Antiviral-Treated HCV Patients: A 3-Year Prospective Cohort Study

Background/Aim: The recovery pattern of hepatitis C virus (HCV)-associated metabolic alteration after sustained virological response (SVR) following direct-acting antivirals (DAAs) remains elusive. Methods: A prospective cohort study of chronic HCV-infected (CHC) patients (n = 415) receiving DAAs (n...

Description complète

Enregistré dans:

Détails bibliographiques
Auteurs principaux:	Heng Lee, Rong-Nan Chien, Li-Heng Pao, Chia-Jung Kuo, Po-Han Huang, Ming-Ling Chang
Format:	article
Langue:	EN
Publié:	MDPI AG 2021
Sujets:	HCV metabolic alteration lipid HOMA-IR DAA Biology (General) QH301-705.5
Accès en ligne:	https://doaj.org/article/23b88b3708994bc7bcaa0a9a98ee95bb
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!

id	oai:doaj.org-article:23b88b3708994bc7bcaa0a9a98ee95bb
record_format	dspace
spelling	oai:doaj.org-article:23b88b3708994bc7bcaa0a9a98ee95bb2021-11-25T17:09:12ZDecoupled Glucose and Lipid Metabolic Recovery after Viral Clearance in Direct-Acting Antiviral-Treated HCV Patients: A 3-Year Prospective Cohort Study10.3390/cells101129342073-4409https://doaj.org/article/23b88b3708994bc7bcaa0a9a98ee95bb2021-10-01T00:00:00Zhttps://www.mdpi.com/2073-4409/10/11/2934https://doaj.org/toc/2073-4409Background/Aim: The recovery pattern of hepatitis C virus (HCV)-associated metabolic alteration after sustained virological response (SVR) following direct-acting antivirals (DAAs) remains elusive. Methods: A prospective cohort study of chronic HCV-infected (CHC) patients (n = 415) receiving DAAs (n = 365) was conducted. Metabolic profiles were examined in SVR patients (n = 360) every 3–6 months after therapy and compared with those of sex- and age-matched controls (n = 470). Results: At baseline, of 415, 168 (40.5%) had insulin resistance (IR). The following were associated: levels of high-density lipoprotein cholesterol (HDL-C), triglycerides (TGs), HCV RNA, fibrosis-4 score, and interferon-λ3-rs12979860 genotype with total cholesterol (TC) levels; and TG levels and BMI with HOMA-IR. Over a 3-year follow-up, in SVR patients, BMI and TC levels and TG/HDL-C ratios increased from baseline, while HOMA-IR trended downward by 72 weeks after therapy and then increased. The increased HDL-C levels began to decrease after 72 weeks after therapy. TC and HOMA-IR were negatively associated with each other until 24 weeks after therapy. Earlier increases in BMI and decreases in HOMA-IR were noted in SVR patients with than in those without baseline IR. Compared with controls, in the subgroup without baseline IR, SVR patients had increased BMI and HOMA-IR levels. Metabolic profiles were similar between SVR patients and controls in the subgroup with baseline IR. Conclusions: In SVR patients treated with DAAs, the recovery of altered lipid and glucose metabolism was not coupled until 72-week post-therapy, when HOMA-IR reached its nadir. SVR patients with baseline IR recovered from HCV-associated metabolic alterations earlier than those without baseline IR.Heng LeeRong-Nan ChienLi-Heng PaoChia-Jung KuoPo-Han HuangMing-Ling ChangMDPI AGarticleHCVmetabolic alterationlipidHOMA-IRDAABiology (General)QH301-705.5ENCells, Vol 10, Iss 2934, p 2934 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	HCV metabolic alteration lipid HOMA-IR DAA Biology (General) QH301-705.5
spellingShingle	HCV metabolic alteration lipid HOMA-IR DAA Biology (General) QH301-705.5 Heng Lee Rong-Nan Chien Li-Heng Pao Chia-Jung Kuo Po-Han Huang Ming-Ling Chang Decoupled Glucose and Lipid Metabolic Recovery after Viral Clearance in Direct-Acting Antiviral-Treated HCV Patients: A 3-Year Prospective Cohort Study
description	Background/Aim: The recovery pattern of hepatitis C virus (HCV)-associated metabolic alteration after sustained virological response (SVR) following direct-acting antivirals (DAAs) remains elusive. Methods: A prospective cohort study of chronic HCV-infected (CHC) patients (n = 415) receiving DAAs (n = 365) was conducted. Metabolic profiles were examined in SVR patients (n = 360) every 3–6 months after therapy and compared with those of sex- and age-matched controls (n = 470). Results: At baseline, of 415, 168 (40.5%) had insulin resistance (IR). The following were associated: levels of high-density lipoprotein cholesterol (HDL-C), triglycerides (TGs), HCV RNA, fibrosis-4 score, and interferon-λ3-rs12979860 genotype with total cholesterol (TC) levels; and TG levels and BMI with HOMA-IR. Over a 3-year follow-up, in SVR patients, BMI and TC levels and TG/HDL-C ratios increased from baseline, while HOMA-IR trended downward by 72 weeks after therapy and then increased. The increased HDL-C levels began to decrease after 72 weeks after therapy. TC and HOMA-IR were negatively associated with each other until 24 weeks after therapy. Earlier increases in BMI and decreases in HOMA-IR were noted in SVR patients with than in those without baseline IR. Compared with controls, in the subgroup without baseline IR, SVR patients had increased BMI and HOMA-IR levels. Metabolic profiles were similar between SVR patients and controls in the subgroup with baseline IR. Conclusions: In SVR patients treated with DAAs, the recovery of altered lipid and glucose metabolism was not coupled until 72-week post-therapy, when HOMA-IR reached its nadir. SVR patients with baseline IR recovered from HCV-associated metabolic alterations earlier than those without baseline IR.
format	article
author	Heng Lee Rong-Nan Chien Li-Heng Pao Chia-Jung Kuo Po-Han Huang Ming-Ling Chang
author_facet	Heng Lee Rong-Nan Chien Li-Heng Pao Chia-Jung Kuo Po-Han Huang Ming-Ling Chang
author_sort	Heng Lee
title	Decoupled Glucose and Lipid Metabolic Recovery after Viral Clearance in Direct-Acting Antiviral-Treated HCV Patients: A 3-Year Prospective Cohort Study
title_short	Decoupled Glucose and Lipid Metabolic Recovery after Viral Clearance in Direct-Acting Antiviral-Treated HCV Patients: A 3-Year Prospective Cohort Study
title_full	Decoupled Glucose and Lipid Metabolic Recovery after Viral Clearance in Direct-Acting Antiviral-Treated HCV Patients: A 3-Year Prospective Cohort Study
title_fullStr	Decoupled Glucose and Lipid Metabolic Recovery after Viral Clearance in Direct-Acting Antiviral-Treated HCV Patients: A 3-Year Prospective Cohort Study
title_full_unstemmed	Decoupled Glucose and Lipid Metabolic Recovery after Viral Clearance in Direct-Acting Antiviral-Treated HCV Patients: A 3-Year Prospective Cohort Study
title_sort	decoupled glucose and lipid metabolic recovery after viral clearance in direct-acting antiviral-treated hcv patients: a 3-year prospective cohort study
publisher	MDPI AG
publishDate	2021
url	https://doaj.org/article/23b88b3708994bc7bcaa0a9a98ee95bb
work_keys_str_mv	AT henglee decoupledglucoseandlipidmetabolicrecoveryafterviralclearanceindirectactingantiviraltreatedhcvpatientsa3yearprospectivecohortstudy AT rongnanchien decoupledglucoseandlipidmetabolicrecoveryafterviralclearanceindirectactingantiviraltreatedhcvpatientsa3yearprospectivecohortstudy AT lihengpao decoupledglucoseandlipidmetabolicrecoveryafterviralclearanceindirectactingantiviraltreatedhcvpatientsa3yearprospectivecohortstudy AT chiajungkuo decoupledglucoseandlipidmetabolicrecoveryafterviralclearanceindirectactingantiviraltreatedhcvpatientsa3yearprospectivecohortstudy AT pohanhuang decoupledglucoseandlipidmetabolicrecoveryafterviralclearanceindirectactingantiviraltreatedhcvpatientsa3yearprospectivecohortstudy AT minglingchang decoupledglucoseandlipidmetabolicrecoveryafterviralclearanceindirectactingantiviraltreatedhcvpatientsa3yearprospectivecohortstudy
_version_	1718412636212690944

Decoupled Glucose and Lipid Metabolic Recovery after Viral Clearance in Direct-Acting Antiviral-Treated HCV Patients: A 3-Year Prospective Cohort Study

Documents similaires